{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(17)"],"submitter":["Parente P"],"pubmed_abstract":["<h4>Introduction</h4>Colorectal cancer (CRC) is the third most frequent malignancy and the second cause of cancer-related death worldwide. CRC is characterized by morphologic and biological heterogeneity, and molecular profiling is required to select appropriate treatment in the metastatic setting. Mutations in <i>KRAS</i> are detected in approximately 40% of CRCs, with prognostic and predictive value, and with the most frequent being p.G12D. Nonetheless, there are few data on the morphologic features in <i>KRAS</i>-mutated CRCs.<h4>Materials and methods</h4>We retrospectively collected clinicopathological features and molecular profiles of CRCs in a multicenter cohort.<h4>Results</h4>A total of 2816 patients from 12 centers were included. <i>KRAS</i> mutation was found in 47.4% of cases; "],"journal":["Cancers"],"pagination":["2721"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12427293"],"repository":["biostudies-literature"],"pubmed_title":["&lt;i&gt;KRAS&lt;/i&gt; Mutations in Colorectal Adenocarcinoma: Incidence and Association with Histological Features with Particular Reference to &lt;i&gt;Gly12Asp&lt;/i&gt; in a Multicenter GIPAD Real-World Study."],"pmcid":["PMC12427293"],"pubmed_authors":["Antoci F","Ascione A","Ambrosio MR","Gafa R","Pasculli B","Pilozzi E","Vasuri F","Vanoli A","Parente P","Giobbe M","Fassan M","Grillo F","Adotti F","Macciomei MC","Mastracci L","Lanza G","Petrelli F","Angerilli V","Gasparello J","Caputo A","Gandolfi L","Melocchi L","Parrella P","Scarpino S","Veccia N","Saragoni L"],"additional_accession":[]},"is_claimable":false,"name":"&lt;i&gt;KRAS&lt;/i&gt; Mutations in Colorectal Adenocarcinoma: Incidence and Association with Histological Features with Particular Reference to &lt;i&gt;Gly12Asp&lt;/i&gt; in a Multicenter GIPAD Real-World Study.","description":"<h4>Introduction</h4>Colorectal cancer (CRC) is the third most frequent malignancy and the second cause of cancer-related death worldwide. CRC is characterized by morphologic and biological heterogeneity, and molecular profiling is required to select appropriate treatment in the metastatic setting. Mutations in <i>KRAS</i> are detected in approximately 40% of CRCs, with prognostic and predictive value, and with the most frequent being p.G12D. Nonetheless, there are few data on the morphologic features in <i>KRAS</i>-mutated CRCs.<h4>Materials and methods</h4>We retrospectively collected clinicopathological features and molecular profiles of CRCs in a multicenter cohort.<h4>Results</h4>A total of 2816 patients from 12 centers were included. <i>KRAS</i> mutation was found in 47.4% of cases; ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-04-23T03:19:04.592Z","creation":"2026-04-23T03:11:23.844Z"},"accession":"S-EPMC12427293","cross_references":{"pubmed":["40940818"],"doi":["10.3390/cancers17172721"]}}